Hi SoT, I find myself in partial agreement only with your thoughts of D-I-Y philosophy. Whilst attractive for full revenues staying inhouse, we have to get it/them fully approved first, and there-in can lie problems. We would not be the first company with a life changing drug to suffer at the hands of FDA for not holding hands with a BP company! BP can and does gr’eze’ the wheel's thru the system and/or obfuscate the process! They also provide a ready made network for market distribution if/when approved. Pros and cons either way imho.
Ann: 2023 AGM Chairman's Address and CEO Presentation, page-37
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
12.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $559.9M | |||
| Open | High | Low | Value | Volume |
| 12.5¢ | 12.5¢ | 12.0¢ | $185.3K | 1.515M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 166662 | 12.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.5¢ | 39575 | 3 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| PYC (ASX) Chart |